United Kingdom & European Union — European Medicines Agency
14 shared events · Importance 7 · Last updated Jun 25, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United Kingdom: The United Kingdom participated in the PAES study, contributing to the data that supports the efficacy and safety of Imlifidase.
European Union — European Medicines Agency: The European Union — European Medicines Agency conditionally approved Imlifidase and requested the PAES study, which has now been successfully completed, paving the way for a full marketing authorization application.
May 27, 2026 · 6 articles
Regulatory
United Kingdom: The United Kingdom is the first country where INmune Bio Inc. has received a key regulatory approval for Ebstrocel, paving the way for a Marketing Authorization Application (MAA) and potential market access for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
Business
United Kingdom: The United Kingdom>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
May 19, 2026 · 7 articles
Tech
United Kingdom: The United Kingdom is providing up to £20 million to contain the Ebola outbreak in the Democratic Republic of the Congo and Uganda, supporting international efforts and frontline health workers.
European Union — European Medicines Agency: The European Union — European Medicines Agency approved a different Ebola vaccine in 2020, demonstrating its role in regulating and approving medical treatments.
May 22, 2026 · 36 articles
Business
United Kingdom: The United Kingdom is one of the countries where additional regulatory filings are planned for Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
European Union — European Medicines Agency: The European Union — European Medicines Agency has granted orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification, and priority medicines (PRIME) designation to Allogeneic umbilical cord-derived CD34- cells, non-expanded/dorocubicel.
Jun 10, 2026 · 6 articles
Business
United Kingdom: The UK is one of the countries where Pharmanovia gains exclusive rights to commercialize senaparib.
European Union — European Medicines Agency: The EMA accepted the Marketing Authorisation Application for senaparib, a regulatory step that is critical for European Union — European market entry. Approval is expected in H2 2026.
Jul 31, 2026 · 8 articles
Domestic
United Kingdom: The UK previously narrowed its COVID-19 vaccination programme to older adults, care home residents, and immunocompromised individuals.
European Union — European Medicines Agency: EMA oversees vaccine safety in the EU and received confidential documents from BioNTech regarding adverse events, but the policy change is a national decision.
Jul 13, 2026 · 6 articles
Business
United Kingdom: The UK is one of the markets where Idefirix is conditionally approved, part of the product's European footprint.
European Union — European Medicines Agency: The EMA's prior conditional approval and PRIME designation support Idefirix's regulatory standing in Europe, though not directly impacted by this event.
Aug 18, 2026 · 6 articles
Business
United Kingdom: The United Kingdom is mentioned as a country with which India has signed a similar trade deal, indicating India's broader strategy for trade agreements.
European Union — European Medicines Agency: Indian generic medicines approved by the European Union — European Medicines Agency>>> will receive fast-track marketing authorization in Oman>>> under the CEPA.
May 29, 2026 · 79 articles
Business
United Kingdom: Cosmos Health has operations in the UK; the buyback does not directly affect the country.
European Union — European Medicines Agency: The EMA certifies Cana Laboratories; the buyback has no direct impact on this relationship.
Jun 30, 2026 · 63 articles
Tech
European Union — European Medicines Agency: The European Union — European Medicines Agency reviewed IDEFIRIX as part of its PRIority Medicines program, supporting its conditional marketing approval in Europe.
May 25, 2026 · 6 articles
Business
European Union — European Medicines Agency: The European Union — European Medicines Agency certifies Abbott Laboratories's manufacturing practices, ensuring compliance with European Good Manufacturing Practices.
Jun 18, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United Kingdom and European Union — European Medicines Agency interact across events, view sentiment trends, and discover connected entities.
Open Dashboard